Sign In
Buy NVRO
$5.84
+0 (+0%)
At Close: Jul 01, 2025
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
09:06am, Tuesday, 17'th Dec 2024
NVRO's continued technological innovations and business diversification plans raise optimism about the stock.
Bet on 5 Top-Ranked Stocks With Rising P/E
08:05am, Tuesday, 10'th Dec 2024
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX.
Nevro resumed with an Equal Weight at Wells Fargo
05:49am, Tuesday, 03'rd Dec 2024
Wells Fargo resumed coverage of Nevro with an Equal Weight rating and $5 price target. Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were s
NVRO Stock Declines Despite Positive Study Data of Nevro1 System
10:30am, Tuesday, 19'th Nov 2024
Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System.
Furthering Nevro's body of evidence as an innovation leader in pain management, da ta highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif. , Nov. 18, 2024 /PRNe
Nevro Stock May Gain on the CE Mark Certification for HFX iQ
09:30am, Friday, 15'th Nov 2024
NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
08:30am, Friday, 15'th Nov 2024
REDWOOD CITY, Calif. , Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic p
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y
12:05pm, Tuesday, 12'th Nov 2024
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care*
Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript
09:11pm, Monday, 11'th Nov 2024
Nevro Corp. (NYSE:NVRO ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal -
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
06:21pm, Monday, 11'th Nov 2024
Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago.
Nevro Reports Third-Quarter 2024 Financial Results
04:05pm, Monday, 11'th Nov 2024
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device comp
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy
04:30pm, Tuesday, 29'th Oct 2024
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
04:30pm, Wednesday, 16'th Oct 2024
REDWOOD CITY, Calif. , Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa
